secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2023-11-28T23:59:59+00:00
Accession:  0001367644-23-000199
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions gets $75M BARDA contract option for CYFENDUS anthrax vaccine
--------------------------------------------------------------------------------

- BARDA exercised a $75 million option under contract HHSO100201600030C for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted).
- Deliveries begin in 2023 and are expected to be complete by end of Q1 2024.
- CYFENDUS was approved by FDA in July 2023 as a two-dose post-exposure prophylaxis for ages 18+.
- The vaccine supports U.S. anthrax preparedness strategy and is part of Emergent's medical countermeasures franchise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000199/0001367644-23-000199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000199/ebs-20231121.htm
  HTML page:      https://secwatch.observer/filing/0001367644-23-000199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer